The global landscape of clinical trials for avian influenza vaccines is witnessing a notable upswing, marked by a continuous increase in both the quantity and diversity of trials conducted worldwide. This surge is characterized by a discernible net rise in the initiation of new influenza vaccine clinical trials and the sustained progress of ongoing trials. The momentum in clinical research underscores a proactive and expansive approach to addressing the challenges posed by avian influenza through the development of effective vaccines.
A significant illustration of this trend can be observed in the landscape of clinical trials as of March 2018. At this juncture, two Phase II studies, spearheaded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the esteemed National Institutes of Health (NIH), took center stage. These studies were designed to rigorously evaluate various dosages of the inactivated influenza vaccine candidate known as 2017 H7N9 IIV. Additionally, diverse vaccination schedules were under scrutiny, reflecting a meticulous effort to optimize the vaccine's effectiveness.
Furthermore, the Butantan Institute, a prominent research institution, embarked on Phase I studies encompassing a range of influenza vaccine candidates. These candidates included combinations such as H7N9 antigen with adjuvant IB160, H7N9 antigen with adjuvant SE, and H7N9 antigen without adjuvant. The diverse array of vaccine formulations under investigation highlights the multifaceted nature of the research being undertaken to combat avian influenza effectively.
Brazil has emerged as a focal point for this intensified clinical research effort, with notable institutions such as Hospital das ClÃnicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Centro de Pesquisas ClÃnicas do Instituto Central do Hospital das ClÃnicas da Faculdade de Medicina da Universidade de São Paulo, and Centro de Pesquisa ClÃnica do Instituto da Criança do Hospital das ClÃnicas da Faculdade de Medicina da Universidade de São Paulo actively recruiting candidates for these pivotal studies. This collaborative and geographically diverse approach to clinical trials signifies a concerted global effort to advance the understanding and development of avian influenza vaccines.
The burgeoning number of clinical trials is not merely a statistical metric but holds profound implications for the future of avian influenza prevention. The anticipated outcome of this increased research activity is the introduction of novel products into the market in the forthcoming years. The proactive pursuit of clinical trials is poised to contribute substantially to the growth of the avian influenza vaccine market, reinforcing the notion that sustained research efforts translate into tangible advancements in vaccine development and subsequent market expansion.
In essence, the escalating number of clinical trial candidates for avian influenza vaccines reflects a global commitment to addressing the challenges posed by this infectious disease. The concurrent exploration of diverse formulations and vaccination schedules signifies a nuanced and comprehensive approach to vaccine development. As these trials progress, the potential for launching new and improved products into the market looms large, promising a future where the global community is better equipped to combat the threat of avian influenza through the power of scientific research and innovation.
Covered Aspects:
Report Attribute/Metric |
Details |
Base Year For Estimation |
  2019 |
Historical Data |
2020 |
Forecast Period |
  2023-2032 |
Growth Rate |
  7.5% |
Avian Influenza Vaccine Market Highlights:
Avian Influenza Vaccine Market Overview
The Avian Influenza Vaccine market is anticipated to reach USD 1.18 Billion 2032 at a CAGR 7.5% during the forecast period 2023-2032.
 Avian influenza, also known as bird flu, is a viral infection that spreads from bird to bird and can infect other animals or humans also. There are different strains of avian influenza, causing the infection, but H5V1 is the most common virus strain affecting poultry animals.
Market Dynamics
The increasing strategic agreements are expected to drive market growth during the study period. For instance, in February 2018, the NC State College of Veterinary Medicine and Ceva Santé Animale, an animal health company, based in France, collaborated on a distance learning project providing certification in poultry health management for veterinarians in Latin America. Moreover, the increasing public & private initiatives by the government as well as non-government organizations for research & development are also anticipated to drive the market growth.
Avian Influenza Vaccine Market, by Strain, 2018 & 2025 (USD Million)
Source: MRFR Analysis
Segmentation
The Avian Influenza Vaccine Market has been segmented by strain and application. The market, based on strain, has been bifurcated into H5, H7, and H9. Based on application, the avian influenza vaccine market has been chicken, turkey, and goose & duck.
Africa Avian Influenza Vaccine Market Share, 2018 (%)
Source: MRFR Analysis
Regional Analysis
The Avian Influenza Vaccine Market, based on region, has been divided into the APAC & Middle East, Europe, Americas, and Africa.
The APAC & Middle East is likely to dominate the avian influenza vaccine market. This can be attributed to the increasing production of poultry birds and the rise in avian influenza outbreaks in the region. According to a recent report from the Foreign Agricultural Service/USDA, China recorded 13,800 thousand metric tons of chicken meat production in 2019. Furthermore, various government initiatives for rapid and effective response efforts to emergent zoonotic influenza viruses are also expected to drive market growth.
The European market for the avian influenza vaccine is estimated to be the second-largest during the review period. The growing dependence on poultry as the key source of protein in the diet in this region is expected to boost the growth of the regional market. According to the European Commission, the European Union (EU) produced 15.2 million tons of poultry meat in 2018. Additionally, increasing the production of veterinary products and improved animal husbandry practices in Germany and Poland are further fueling market growth.
Americas is estimated to demonstrate significant market growth owing to the growing meat & poultry industry, the increasing expenditure on animal health, and the presence of a large number of veterinary hospitals in the region. According to the North American Meat Institute, the US exported 3.7 million metric tons (MT) of poultry and poultry variety meats in 2017. The value was estimated at USD 4.5 billion. Moreover, growing government support for creating awareness on avian influenza viruses and improving efficiency for the avian influenza vaccine is also positively affecting the market growth.
Key Players
The Prominent Players in the Avian Influenza Vaccine Market are Boehringer Ingelheim International GmbH (Germany), Guangdong Wenshi Dahuanong Biotechnology Co., Ltd (China), Ceva (US), Yebio Bioengineering Co., Ltd (China), Zoetis (US), FATRO S.P.A. (Italy), CAVAC (South Korea), Tianjin Ringpu Bio-Technology Co., Ltd (China), PT Japfa Comfeed Indonesia Tbk (Indonesia), Chengdu Tech-bank Biological Products Co., Ltd (China), Merck Animal Health (US), Medion (Indonesia), Avimex Animal Health (Mexico), JOVAC (Jordan), and QYH BIOTECH COMPANY LIMITED (China). Some of the key strategies followed by players operating in the avian influenza vaccine market were collaborations, acquisition, product approval & launch, and expansion.
-
In October 2019, Ceva and ProBioGen AG signed an exclusive license agreement for the manufacture of vectorized poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.
-
In October 2018, Boehringer Ingelheim announced the opening of its biological research and development site in France. It invested USD 80.45 million (EUR 70 million) for maintaining its leading position in veterinary vaccines.
-
In August 2017, Merck Animal Health announced the plans to purchase a new manufacturing facility in Austria. With this purchase, the company was intended to expand its global vaccine manufacturing capacity.
-
In March 2016, Zoetis announced that the US Department of Agriculture (USDA) granted the company a conditional license for Avian Influenza Vaccine, H5N1 Subtype, and Killed Virus.
Market Segmentation
Avian Influenza Vaccine Market, by Strain
Avian Influenza Vaccine Market, by Application
- Chicken
- Turkey
- Duck & Goose
Avian Influenza Vaccine Market, by Region
-
APAC & Middle East
- China
- Philippines
- Vietnam
- India
- Bangladesh
- Cambodia
- Indonesia
- Iran
- Thailand
- Pakistan
- Rest of APAC & Middle East
-
Europe
- Germany
- Bulgaria
- Poland
- Hungary
- Ukraine
- Czech Republic
- Rest of Europe
-
Americas
- US
- Brazil
- Mexico
- Argentina
- Columbia
- Rest of the Americas
-
Africa
- South Africa
- Nigeria
- Ghana
- Cameroon
- Rest of Africa
Available Additional Customizations
- Challenges in the Avian Influenza Vaccine Market
- Investment Opportunities in the Avian Influenza Vaccine Market
Intended Audience
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations
- Research & development organizations
- Academic institutes